27 results
Primary objective of the study: 1. To report on the effectmodification by age of MPH treatment on the outgrowth of the DA system using state-of-the-art Magnetic Resonance Imaging (MRI) techniquesSecondary objectives:1. To report on the…
Primary Objective:The primary objective in the current trial is to use graph theory to examine how the organization of the functional brain network may be altered by the administration of methylphenidate. The main question we intend to answer in…
The primary aim of our study will be to investigate the effectiveness of PCIT in comparison with methylphenidate in children with ADHD and disruptive behavior problems aged 2;6 till 6 years who have not responded sufficiently to previously offered…
The aim of the trial is to obtain data on the optimal dose, feasibility and pharmacokinetics of bumetanide when given as an add-on treatment for seizures in full term babies with hypoxic ischemic encephalopathy (HIE). Bumetanide will be given in a…
To replicate and extend the findings of the recent methylphenidate study in which methylphenidate was found to enhance episodic memory performance; To explore whether this effect of methylphenidate is primarily mediated by its dopaminergic action.
The primary objectives of the iSPOT-A trial are to use Brain Resource's standardized 'Integrative Neuroscience' test batteries to 1) Identify objective markers of ADHD compared with healthy controls, using cognitive, brain and genetic…
This study is an attempt to seriously investigate one of the most plausible reasons for the difference in effectiveness of MPH in the treatment of adult ADHD patients with and without SUD.
Primary:The primary objective of this study is to evaluate the efficacy of LDX administered as a daily morning dose (30, 50, and 70mg/day) compared to placebo over the course of 7 weeks. This study will enrol children and adolescents (6-17 years of…
The objectives of this study are to establish whether methylphenidate PD effects can be measured using neurocognitive tasks, to describe the drug concentrations of methylphenidate in saliva, to describe the PK/PD relationship using the obtained…
Primary objective: To investigate the effectiveness of ongoing treatment with methylphenidate as prescribed in clinical practice beyond two years in children and adolescents. Secondary objectives:(1) to investigate the effects of discontinuation of…
We aim to examine, in the impaired older population, whether a treatment using methylphenidate, a DA re-uptake inhibitor that enhances DA, improves attention and memory.
- short-term efficacy of MPH on ADHD symptomatology in adult male SUD patients with ADHD.- short-term influence of MPH on abstinence and drug use- short-term influence of MPH on cocaine craving - safety and adverse effects of MPH in this patient…
The objective of this project is to study the role of dopaminergic mechanisms in apathy, mood and HDD in patients with PD. What is the involvement of the dopaminergic neurotransmitter system in motivation and reward processes in PD and the clinical…
The primary goal of this study is to investigate whether placebo-controlled double-blind titration leads to optimizing the use of methylphenidate. This by detecting placebo-and non-responders more efficiently and by treating responders better so…
To examine the feasibility and acceptability, and preliminary efficacy, of a new developed enhanced CBT (eCBT) for pediatric obsessive-compulsive disorder
Primary aim: to confirm that treatment with bumetanide improves daily life functioning and reduces behavioral symptoms related to hyperexcitability in children and adolescents with TSC.Secondary aim: to identify neurophysiological and cognitive…
The primary objective of the study is to test the effectiveness of bumetanide across the whole spectrum of sensory processing disorders within ASD, ADHD and/or epilepsy. We also want to determine which subgroups (high/low IQ, comorbidities or not)…
The primary objective is to demonstrate the superiority of bumetanide (0.5mg BID) oral liquid formulation compared to placebo in the improvement of ASD core symptoms after 6 months of treatment in ASD children aged from 2 to less than 7 years old.
The primary objective is to demonstrate the superiority of bumetanide (0.5mg BID) oral liquid formulation compared to placebo in the improvement of ASD core symptoms after 6 months of treatment in ASD children and adolescents aged from 7 to less…
The main objective of this study is to compare the acute effects of methylphenidate on behavioral and cognitive functioning in 6 to 12 year old treatment naïve children compared to the effects after nine months of treatment with methylphenidate in…